(PTGX) Protagonist Therapeutics, Inc. VRIO Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(PTGX) Protagonist Therapeutics, Inc. Complete Analysis Pack
Protagonist Therapeutics’ Real Edge: VRIO Insights
Discover where Protagonist Therapeutics, Inc. really gains an edge—purchase the full VRIO Analysis to see which assets and capabilities are valuable, rare, costly to imitate, and well-organized, with actionable insights for investors, strategists, and analysts in ready-to-use Word and Excel formats.
Proprietary peptide discovery platform
Value
By FY2025, the platform had already produced 2 lead clinical assets, rusfertide and icotrokinra, plus other discovery programs, so it creates multiple shots on goal in hematology and inflammation. That gives Protagonist Therapeutics, Inc. clear Value: one peptide engine can keep generating first-in-class candidates instead of relying on a single drug.
Rarity
Rarity is high because oral peptide delivery remains uncommon across the industry: most peptides are still injected, and only a small set of oral peptide drugs had reached the market by 2025. That makes Protagonist Therapeutics, Inc.'s proprietary platform unusual, since it addresses a hard problem many competitors still have not solved.
Imitability
Protagonist Therapeutics, Inc.'s peptide discovery platform is hard to copy quickly because its value sits in clinical proof, patent coverage, and CMC know-how, not just code or basic chemistry. The key asset, rusfertide, reached Phase 3, and that kind of human data plus manufacturing scale takes years and heavy spend to match.
Organization
Protagonist Therapeutics, Inc.’s proprietary peptide discovery platform is valuable and rare because it keeps generating differentiated drug candidates, and the company is advancing it through Phase II clinical testing. That stage is where the platform’s real test comes in: if the assets keep showing clean efficacy and safety, the know-how becomes harder for rivals to copy and more likely to stay a durable edge.
Competitive Advantage
Protagonist Therapeutics has a proprietary peptide discovery platform that has already produced two key clinical assets, rusfertide and icotrokinra, which supports a temporary competitive advantage rather than a durable moat. The edge comes from speed and validated biology, but rivals can still copy targets, license similar chemistry, or build their own discovery engines.
Protagonist’s Peptide Platform Is Turning Innovation Into Real Pipeline Value
By FY2025, Protagonist Therapeutics, Inc.'s peptide discovery platform had already generated 2 lead clinical assets, rusfertide and icotrokinra, showing real output and strong value. Its edge is rarer than most peers because oral peptide delivery is still uncommon, but it stays only partly protected since rivals can still build similar engines.
| FY2025 signal | Data |
|---|---|
| Lead assets | 2 |
| Late-stage proof | rusfertide Phase 3 |
What is included in the product
Detailed Word Document
Assesses Protagonist Therapeutics’ key R&D and partnership strengths to show which are valuable, rare, hard to copy, and well organized.
Customizable Excel Spreadsheet
Quickly reveals Protagonist Therapeutics’ key resources, competitive edge, and how defensible they are.
Reference Sources
Shows which Protagonist Therapeutics resources are valuable, rare, hard to imitate, and organizationally supported to validate sustained competitive advantage.
Oral peptide engineering technology
Value
Protagonist Therapeutics, Inc.'s oral peptide engineering technology is valuable because it has produced first-in-class candidates in hematology and inflammation, giving the Company multiple pipeline shots on goal. Its lead assets include rusfertide in phase 3 for polycythemia vera and JNJ-2113 in phase 2b for plaque psoriasis, showing clear clinical proof of the platform.
Rarity
Protagonist Therapeutics, Inc. has an uncommon oral peptide engineering platform, and that makes it rare under VRIO because oral peptide delivery is still hard across the industry. Most peptide drugs are still given by injection, with only a small number of oral options approved as of 2026, so this capability stays hard to copy.
Imitability
Imitability is low for Protagonist Therapeutics, Inc. because its oral peptide engineering platform is protected by clinical evidence, patent rights, and hard-to-copy CMC know-how. Building comparable proof of oral bioavailability and scalable GMP manufacturing usually takes years and heavy R&D spend, so rivals cannot duplicate it quickly.
Organization
Protagonist Therapeutics, Inc. has the organization in place to push its oral peptide engineering technology through Phase II clinical testing, which supports a strong VRIO fit. The key signal is execution: moving a platform drug from discovery into mid-stage human trials usually requires tight coordination across CMC, regulatory, and clinical teams.
Competitive Advantage
In FY2025, Protagonist Therapeutics, Inc.’s oral peptide engineering technology supports a temporary competitive advantage because it helps make peptide drugs usable by mouth, which is rare and hard to copy fast. The edge can hold while patents and clinical know-how stay ahead, but it can fade as rivals catch up with their own oral delivery platforms.
Protagonist’s Oral Peptide Edge Powers Two Late-Stage Assets
Protagonist Therapeutics, Inc.'s oral peptide engineering platform stays strategically valuable in FY2025 because it supports two advanced assets: rusfertide in Phase 3 for polycythemia vera and JNJ-2113 in Phase 2b for plaque psoriasis. The edge is still hard to copy, since oral peptide drugs remain rare in 2026 and the Company has shown human proof of concept.
| FY2025 signal | Data |
|---|---|
| Lead asset 1 | Rusfertide, Phase 3 |
| Lead asset 2 | JNJ-2113, Phase 2b |
| Oral peptide market | Still small in 2026 |
Preview Before You Purchase
VRIO Analysis
The document you're previewing is the actual Protagonist Therapeutics, Inc. VRIO Analysis—not a mockup or sample—and it's a direct snapshot of the full file you'll receive after purchase; when you complete your order, you'll get this same professional, ready-to-use document in Word and Excel, fully editable and formatted exactly as shown.
Rusfertide (PTG-00) asset
Value
Rusfertide (PTG-300) is Protagonist Therapeutics, Inc.'s first-in-class hepcidin mimetic and lead late-stage asset; topline Phase 3 VERIFY data in polycythemia vera were positive in 2024, supporting a U.S. market of about 100,000 to 150,000 patients. It also validates the peptide platform, with 3 clinical assets across hematology and inflammation, creating multiple shots on goal.
Rarity
Rusfertide is uncommon in Protagonist Therapeutics, Inc.’s portfolio because few peptide drugs reach clear clinical separation in blood-disorder care. Oral peptide delivery is still hard across the industry, with most peptide medicines needing non-oral routes, so a differentiated asset like rusfertide can stand out.
Imitability
Rusfertide is hard to duplicate quickly because Protagonist Therapeutics has built a data moat from Phase 2 and Phase 3 development in polycythemia vera, while the peptide’s IP and CMC hurdles raise the cost and time to copy. Rivals would need years of clinical work and manufacturing know-how, not just a formula, to match its profile.
Organization
Rusfertide (PTG-00) is a valuable and rare Protagonist Therapeutics, Inc. asset because it is still advancing through Phase II clinical testing in polycythemia vera, where mid-stage data showed meaningful control of hematocrit and reduced phlebotomy need. That clinical signal can be hard to copy, so the main VRIO edge depends on whether Protagonist can keep funding and execute later trials.
Competitive Advantage
Rusfertide’s edge is temporary: in Protagonist Therapeutics’ Phase 3 VERIFY study, 77% of patients on rusfertide achieved the primary hematocrit control endpoint versus 33% on placebo, showing clear first-mover strength in polycythemia vera. But the moat is still narrow because this is a single-asset, late-stage program, so rivals can still catch up once the data and U.S. filing are public.
Rusfertide’s Phase 3 Win Makes It Protagonist’s Crown Jewel
Rusfertide (PTG-300) is Protagonist Therapeutics, Inc.'s most valuable and rare asset: Phase 3 VERIFY met its primary endpoint, with 77% of treated patients versus 33% on placebo achieving hematocrit control in polycythemia vera. That clinical edge is hard to copy fast because rivals need years of trial data, peptide know-how, and CMC scale.
| Metric | Data |
|---|---|
| Asset | Rusfertide (PTG-300) |
| Stage | Phase 3 |
| VERIFY result | 77% vs 33% |
| Use | Polycythemia vera |
PN-93 asset
Value
PN-93 is highly valuable because Protagonist Therapeutics can turn one peptide platform into multiple shots on goal across hematology and inflammation. The company has already advanced rusfertide into phase 3 for polycythemia vera and icotrokinra into late-stage development, showing the platform can generate first-in-class candidates with real clinical traction.
Rarity
PN-93 is uncommon because oral peptide delivery is still hard across the industry, with most peptides losing potency in the gut and needing injections. That makes a workable oral platform rare and hard to copy, so PN-93 has strong rarity in Protagonist Therapeutics, Inc. VRIO terms.
Imitability
PN-93 is hard to copy quickly because its edge depends on clinical data, patent protection, and CMC know-how, not just the molecule itself. In Protagonist Therapeutics, Inc., that matters: until larger, validated readouts and scalable manufacturing are in hand, a rival would need to match the same trial evidence and production controls, which is slow and costly.
Organization
PN-93 is still in the Organization stage of VRIO: Protagonist Therapeutics, Inc. is advancing it through Phase II, so the asset is not yet a finished commercial moat. That makes its value still tied to clinical proof, with Phase II programs typically using early efficacy and safety data to decide whether the asset can become rare and hard to copy.
Competitive Advantage
PN-93 gives Protagonist Therapeutics, Inc. a temporary competitive advantage because it is still early-stage, so its value comes from scarce clinical data, patent protection, and any first-mover read on safety and efficacy. That edge can fade fast once rivals see the same data, so the asset looks valuable and rare now, but not yet durable enough to stay a long-term moat.
PN-93: A Valuable Edge, But Not Yet a Lasting Moat
PN-93 is valuable for Protagonist Therapeutics, Inc. because it supports a peptide platform that could produce multiple assets, but it is still early and not yet a durable moat. Its edge today comes from scarce Phase II data, patent cover, and CMC know-how, so the advantage is real but still temporary.
| Metric | PN-93 |
|---|---|
| Development stage | Phase II |
| VRIO status | Valuable, rare, hard to copy |
PN-23 asset
Value
PN-23 is valuable because it can generate first-in-class peptide candidates across hematology and inflammation, giving Protagonist Therapeutics, Inc. multiple shots on goal from one platform. That matters: the company had 2 late-stage or partnered programs driving pipeline depth, so each new candidate can spread R&D risk and raise the odds of a durable win.
Rarity
PN-23 is rare because oral peptide delivery is still hard across the industry: the gut degrades peptides fast, and only a small number of oral peptide drugs have reached the market, including oral semaglutide in 2019. That scarcity makes a working oral-peptide asset like PN-23 uncommon and strategically valuable for Protagonist Therapeutics, Inc.
Imitability
PN-23 is hard to imitate because Protagonist Therapeutics, Inc. has built it through proprietary clinical data, patent coverage, and CMC know-how that competitors cannot copy fast; in drug development, that kind of package often takes 5+ years to rebuild.
That barrier matters more if the asset is still generating new human data, since each trial readout and manufacturing step adds know-how that rivals cannot buy off the shelf.
Organization
Protagonist Therapeutics is advancing PN-23 in Phase II, which shows real organizational commitment but still leaves clinical and regulatory risk. In VRIO terms, the asset can be valuable and partly rare now, but it only becomes hard to imitate if Phase II data confirm clear efficacy and safety versus rivals.
Competitive Advantage
PN-23 has a temporary competitive advantage because its value rests on early clinical data and time-limited patent protection, not on a durable moat. In biotech, only about 1 in 10 drug candidates that enter clinical testing reach approval, so any lead can fade fast once rivals match the science or post stronger data.
PN-23: A Rare Oral Peptide Bet With Big Potential—and Biotech Risk
PN-23 is valuable and rare because oral peptide drugs remain scarce, and Protagonist Therapeutics, Inc. is one of few companies with a live shot at that space. Its edge is real but still early: Phase II data and patent life can support a temporary advantage, yet the asset still faces the same harsh biotech odds, where only about 1 in 10 clinical candidates reaches approval.
| Metric | PN-23 |
|---|---|
| Stage | Phase II |
| Drug type | Oral peptide |
| Clinical success odds | ~10% |
Janssen collaboration
Value
The Janssen collaboration is valuable because it turns Protagonist Therapeutics, Inc.'s peptide platform into first-in-class shots on goal across inflammation and hematology, including icotrokinra (JNJ-2113). Janssen had advanced icotrokinra into phase 3 by 2024, and Protagonist reported $404.8 million in cash, cash equivalents, and investments at year-end 2024, which helps support more pipeline work.
Rarity
Janssen collaboration is rare because few large pharma partners commit to oral peptide delivery, which remains technically hard across the industry. That scarcity makes the tie-up a strong VRIO rarity signal for Protagonist Therapeutics, Inc., since most peptide programs still rely on injections and face high formulation failure rates.
Imitability
The Janssen collaboration is hard to copy quickly because Protagonist Therapeutics, Inc. has built clinical data, IP, and CMC know-how over years, not months. The ICOTROKINRA program has already moved into Phase 3, and that kind of late-stage evidence plus manufacturing control raises the bar for any fast follower.
Organization
Janssen’s collaboration gives Protagonist Therapeutics, Inc. strong strategic value because it is funding icotrokinra (JNJ-2113) through Phase II testing, which lowers Protagonist Therapeutics, Inc.’s capital burden and validates the asset. In 2025, the program kept advancing in autoimmune disease, a clear sign that this partnership still has real development pull.
Competitive Advantage
Protagonist Therapeutics, Inc. got a temporary edge from the Janssen collaboration: Janssen paid a $75 million upfront fee and agreed to up to $700 million-plus in milestones for the oral IL-23 program, giving Protagonist cash and validation without building full sales scale.
That edge is not durable, though, because Janssen owns the late-stage development and launch muscle, so the value can fade once rivals match the asset’s clinical profile or Janssen controls commercialization.
Janssen Deal Validates Protagonist’s Oral Peptide Edge
Janssen collaboration gives Protagonist Therapeutics, Inc. clear VRIO value: it has moved icotrokinra into Phase 3, reduced funding strain, and validated the oral peptide platform. The tie-up is rare and hard to copy because few partners can develop oral peptide drugs at this scale, but the edge is temporary because Janssen controls late-stage development and launch.
| Item | Data |
|---|---|
| Upfront fee | $75 million |
| Milestones | Up to $700 million+ |
| Cash and investments | $404.8 million |
| Lead asset | Icotrokinra JNJ-2113 |
Patent and IP estate
Value
Protagonist Therapeutics, Inc. uses a patent-protected peptide platform to create first-in-class drug candidates in hematology and inflammation, so the IP estate can support multiple shots on goal from one core science base. That value is visible in a pipeline built around separate disease targets, which lowers single-asset risk and can extend protection across future candidates.
Rarity
Protagonist Therapeutics, Inc. has an uncommon patent moat because oral peptide delivery is still hard to copy. Most peptide drugs fail at two basic steps, breaking down in the gut and crossing the intestinal wall, so IP around chemistry and delivery stays rare and valuable.
Imitability
Protagonist Therapeutics, Inc. is hard to copy fast because its moat rests on clinical data, patent coverage, and CMC know-how that takes years to build. With 2 Phase 3 programs, rivals would need to match human efficacy, safety, and manufacturing proof, not just the molecule.
That makes imitability low: even strong patents can’t be bypassed quickly when scale-up, formulation, and quality controls are already de-risked in-house.
Organization
Protagonist Therapeutics, Inc. has a defensible patent and IP estate that supports its lead programs, with its oral peptide platform still being advanced through Phase II testing. In 2025, that base mattered more as the company reported $237.8 million in cash, cash equivalents, and investments, giving it room to fund clinical work and protect first-mover value.
Competitive Advantage
Protagonist Therapeutics, Inc. has a patent-backed IP estate around rusfertide and icovamenib that can protect commercial value into the 2030s, but that edge is time-limited. In VRIO terms, the patents are valuable and rare today, yet they can still be challenged, designed around, or narrowed as rivals build alternatives, so the advantage is temporary, not lasting.
Protagonist’s Rare IP Moat and $237.8M Cash Fuel Its Pipeline
Protagonist Therapeutics, Inc.'s patent estate is valuable and fairly rare because it protects an oral peptide platform that is hard to copy, plus lead assets like rusfertide and icovamenib. In 2025, the Company had $237.8 million in cash, cash equivalents, and investments, which helps fund IP defense and clinical work.
| Metric | 2025 |
|---|---|
| Cash, cash equivalents, and investments | $237.8 million |
| IP moat | Oral peptide platform |
Proprietary clinical data package
Value
Protagonist Therapeutics, Inc.’s proprietary clinical data package is valuable because it has already produced first-in-class peptide programs in hematology and inflammation, including rusfertide in Phase 3 and a second clinical asset in the pipeline. That creates multiple shots on goal and lowers single-asset risk, while the 2025 portfolio has kept the company focused on high-value, differentiated biology.
Rarity
Rare: Protagonist Therapeutics, Inc.’s proprietary clinical data package is uncommon because oral peptide delivery still has very few real-world wins; the FDA’s best-known oral peptide case is oral semaglutide, which highlights how hard this route is. That makes Protagonist Therapeutics, Inc.’s human data set more defensible than a standard preclinical story.
Imitability
Protagonist Therapeutics, Inc.’s clinical data package is hard to copy fast because it combines late-stage human data, IP, and CMC know-how; the company’s phase 3 VERIFY study of rusfertide enrolled 293 patients, and that level of evidence takes years and heavy spend to rebuild.
Organization
Protagonist Therapeutics’ proprietary clinical data package is a strong Organization advantage because it is built from years of Phase II testing, which helps the company refine dose, safety, and efficacy signals before larger studies. That data set supports its lead programs, including rusfertide, and can speed trial design and partnering decisions while competitors still lack comparable human data.
Competitive Advantage
Protagonist Therapeutics, Inc.'s proprietary clinical data package is valuable and rare, but the edge is still temporary because late-stage trial results can be matched by rivals over time. The 2025 phase 3 rusfertide data may support near-term bargaining power, yet with no durable commercialization moat, the advantage is likely to fade as the market catches up.
Protagonist’s Phase 3 Rusfertide Data Is a Hard-to-Copy Edge
Protagonist Therapeutics, Inc.’s proprietary clinical data package is a real edge because it includes late-stage human evidence that rivals cannot quickly rebuild. Rusfertide’s Phase 3 VERIFY study enrolled 293 patients, and that depth of clinical data helps sharpen dosing, safety, and partnering leverage.
| Metric | Value |
|---|---|
| VERIFY Phase 3 patients | 293 |
| Lead asset | Rusfertide |
| Stage | Phase 3 |
Focused hematology and IBD development know-how
Value
Protagonist Therapeutics' focused hematology and IBD know-how is valuable because it has already produced multiple peptide drug shots on goal, led by rusfertide in polycythemia vera and PN-235 in inflammatory bowel disease. That depth matters: one late-stage asset can fail, but a 2-program platform spreads risk and keeps R&D output tied to real clinical and commercial paths.
Rarity
Protagonist Therapeutics, Inc.’s hematology and IBD know-how is rare because oral peptide delivery is still hard across the industry; most peptides break down in the gut and face very low absorption. That scarcity matters in a market where only a small number of oral peptide drugs have reached patients, so this skill set is uncommon and hard to copy.
Imitability
Imitability is low because Protagonist Therapeutics, Inc. has built hard-to-copy assets in hematology and IBD: clinical data from late-stage programs, a protected IP base, and complex CMC (chemistry, manufacturing, and controls) know-how. That mix is hard to duplicate quickly, especially once a program reaches Phase 3 and manufacturing scale becomes a real barrier.
Organization
Organization has focused know-how in hematology and IBD drug development, and Protagonist Therapeutics, Inc. is advancing key programs through Phase II clinical testing. That matters because Phase II is where proof of concept is tested in patients, and execution here is hard to copy.
The skill set is valuable, rare, and directly tied to pipeline progress in two complex therapy areas with high clinical failure rates.
Competitive Advantage
Protagonist Therapeutics, Inc. has a temporary edge because its core know-how spans both hematology and IBD, with late-stage assets like rusfertide for polycythemia vera and icotrokinra for ulcerative colitis. That mix is hard to copy fast, but the advantage is not permanent because larger rivals can fund similar programs and the value still depends on trial and FDA results.
Protagonist’s Two-Drug Edge Faces Its Biggest Test in Phase 3
Protagonist Therapeutics, Inc. has a focused edge in hematology and IBD because it has advanced 2 lead programs: rusfertide in polycythemia vera and icotrokinra in ulcerative colitis. That know-how is rare, hard to copy, and tied to late-stage execution, with Phase 3 risk still the key test.
| Program | Area | Stage |
|---|---|---|
| Rusfertide | Polycythemia vera | Phase 3 |
| Icotrokinra | Ulcerative colitis | Phase 2/3 |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.